Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.

[1]  B. Potter,et al.  Class III β-tubulin expression and in vitro resistance to microtubule targeting agents , 2009, British Journal of Cancer.

[2]  D. Heo,et al.  Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  T. Masuda,et al.  Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. , 2009, The Journal of investigative dermatology.

[4]  F. Giles,et al.  Microtubule dynamics as a target in oncology. , 2009, Cancer treatment reviews.

[5]  T. Lehman,et al.  The HIF-1α C1772T polymorphism may be associated with susceptibility to clinically localized prostate cancer but not with elevated expression of hypoxic biomarkers , 2009, Cancer biology & therapy.

[6]  G. Scambia,et al.  Molecular mechanisms of patupilone resistance. , 2008, Cancer research.

[7]  M. Coffey,et al.  Hypoxia in prostate cancer: a powerful shield against tumour destruction? , 2008, Cancer treatment reviews.

[8]  G. Scambia,et al.  Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. , 2008, Gene.

[9]  M. Jordan,et al.  How do microtubule-targeted drugs work? An overview. , 2007, Current cancer drug targets.

[10]  R. Hruban,et al.  Class III β‐tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia , 2007, Histopathology.

[11]  M. Hiraoka,et al.  Hypoxia inducible factor‐1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions , 2007, Cancer science.

[12]  R. DiPaola,et al.  Taxane refractory prostate cancer. , 2007, The Journal of urology.

[13]  Shuang-yin Han,et al.  Involvement of MGr1-Ag/37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells , 2007, Molecular and Cellular Biochemistry.

[14]  B. Loftus,et al.  In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer , 2007, British Journal of Cancer.

[15]  F. Rojo,et al.  Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. , 2006, Histology and histopathology.

[16]  J. Verweij,et al.  Clinical Pharmacokinetics of Docetaxel , 2006, Clinical pharmacokinetics.

[17]  P. Giannakakou,et al.  Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. , 2005, Cancer research.

[18]  C Clifton Ling,et al.  Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor mo , 2005, International journal of radiation oncology, biology, physics.

[19]  K. Blackwell,et al.  Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? , 2004, The oncologist.

[20]  S. Skvortsov,et al.  Effects of Paclitaxel and Docetaxel on EGFR-Expressing Human Carcinoma Cells Under Normoxic Versus Hypoxic Conditions In Vitro , 2004, Journal of chemotherapy.

[21]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[22]  C. N. Coleman,et al.  Ibuprofen-mediated Reduction of Hypoxia-inducible Factors HIF-1α and HIF-2α in Prostate Cancer Cells , 2003 .

[23]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[24]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[25]  L. Rivory,et al.  Clinical Pharmacokinetics of Docetaxel , 1999, Clinical pharmacokinetics.

[26]  D. Bostwick,et al.  Microvessel density in prostate cancer: prognostic and therapeutic utility. , 1998, Seminars in urologic oncology.

[27]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[28]  C. Chresta,et al.  Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. , 1996, Cancer research.

[29]  B. Teicher.  Hypoxia and drug resistance , 1994, Cancer and Metastasis Reviews.

[30]  O. Thews,et al.  Impact of hypoxic and acidic extracellular conditions on cytotoxicity of chemotherapeutic drugs. , 2007, Advances in experimental medicine and biology.

[31]  K. Lyseng-Williamson,et al.  Docetaxel: a review of its use in metastatic breast cancer. , 2005, Drugs.

[32]  M. Bissery,et al.  Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. , 1995, Anti-cancer drugs.